Lindsay Rosenwald – His Wall Street Entry

0 comments

Posted on 19th April 2010 by admin in Lindsay Rosenwald Info

,

A founder and also a chairman for Paramount Capital, Dr. Lindsay Rosenwald, performs projects with that assembly of organizations which is mostly involving investment money managing, asset control, plus direct investing and venture capital in the life-science and biotechnological business. The Paramount Capital Asset Management organization uses a mixture of U.S. based and also foreign hedge funds along with private equity for the purpose of managing their investor assets. Paramount Capital is a broker dealer who has FINRA membership and they specialize in helping public and private biotechnology organizations in the initial  stage in supervising private and public placement offerings. The Paramount Capital Investments, LLC organization is a highly focused group whose effort is to take a comprehensive profit in both private and public companies. This includes troubled turn-around and start-up businesses. Paramount BioSciences is both a healthcare investment bank and an worldwide run pharmaceutical item improvement firm. Supplementary to that Dr. Lindsay Rosenwald has a membership with the Managing Member of Orion Biomedical Fund, LP and the Orion Biomedical Offshore Fund, LP. Both of these organizations are managing in Financing. For more than 20 years, Dr. Lindsay Rosenwald has collaborated as a Wall Street capitalist in biotechnology. He has originated and re-capitalized many private and public life-sciences and biotechnology establishments. The portfolio businesses of Paramount have so far invented three different chemical compounds that have been accepted by the FDA and they presently have a considerable number of products that are even still undergoing clinical trials. One of these is a portfolio company known as PolaRx BioPharmaceuticals, Inc., has been granted a final marketing approval for a leukemia compound recognized as arsenic trioxide. This was concluded only 30 months, an industry record, after the treatment of the very first testees was processed in a corporate clinical trial. 5 Other than Cougar Biotechnology, Dr. Lindsay Rosenwald has in addition taken it upon himself to also support or create such companies as Bradley Pharmaceuticals, Inc., Repligen Corporation, Avigen, Inc., Cardiome Pharma Corp., Neose Technologies Inc., Biocryst Pharmaceuticals, Inc, Cypress Bioscience, Inc., Genta, Inc, Discovery Laboratories, Inc., Indevus Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Cell Therapeutics, Inc., and Hudson Health Sciences, Inc. As far as his educational history, Dr. Lindsay Rosenwald was a graduate of Abington High School, in the southeast vicinity of Pennsylvania, back in 1973. He then went on to graduate Beta Gamma Sigma as well as a degree in Finance and Economy from Pennsylvania State University in 1977. Shortly after, he attained employment as a management consultant (working independently), performing for various health care establishments during the years 1977 to 1979 and then entering himself into the Temple University School of Medicine. He graduated from Temple in 1983 and soon afterward was awarded an internship at the Abington Medical Hospital, continuing in the private health system until the year 1986. Dr. Lindsay Rosenwald then moved on to Wall Street in order to syndicate his financial and medical skills and function as a doctor/financial analyst.

Dr. Lindsay Rosenwald reputed himself as a corporate finance managing director for D.H. Blair & Company, in the year of 1988. This was a privately owned investment based business. There, he was the leader of a team of three physician-financiers that sought through the medical community for any new and profitable break-through that could make use of private investment. They located various schools of medicine, universities, hospitals, drug companies, study groups, and scientific firms. Dr. Lindsay Rosenwald then was able to found Paramount BioCapital in 1991. Here, he worked within the biotechnology and bioresearch disciplines. He became a NASD-member dealer in 1992 and established the investment and merchant bank named Paramount Capital Investments LLC, in 1995. Owned by Dr. Lindsay A. Rosenwald, the Paramount Capital Asset Management organization has managed investments from a number of assets since 1994 that have a concentration in the biotechnology and other technological spheres. Dr. Rosenwald serves on the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was ranked number one in the list of 100 Molecular Millionaires with a worth of $617,721,671. Dr. Lindsay Rosenwald operated on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He quit in order to contribute additional time performing in the biotechnology market. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another business that was first founded by Dr. Rosenwald and was originated completely on abiraterone acetate. Abiraterone Acetate, even though it had not yet attained phase III in clinical testing trials, was showing so much potential in the therapy and management for prostate cancer that Johnson & Johnson offered a short-term unification bid and procurement  for the Cougar Biotechnology corporation for $1 billion. Dr. Lindsay Rosenwald, apart from the scores of ventures which have imparted financing and resources to portfolio companies, has also began the Rosenwald Foundation. This is a nonprofit outfit that has been triumphant in offering millions of dollars in aid of many medical and scientific instruction institutions.

Lindsay Rosenwald – Leader In Biotechnology Industry

1 comment

Posted on 8th April 2010 by admin in Home

,

Leaders in the Biotechnology Industry: Dr. Lindsay Rosenwald Lindsay Rosenwald is best known as the founder of the Paramount Group, a group of companies in the biotechnology and bioresearch industry which have fueled the growth of groundbreaking companies over the last two decades.

Rosenwald graduated from Abington High School in Pennsylvania in 1973. He went on to attend Penn State University and graduated as a part of the Betta Gamma Sigma business school honor society in 1977, having received his degree in finance. He then attended Temple University’s School of Medicine where he receive his doctorate in 1983. He began work in Abington Medical Hospital but started a private practice soon thereafter. Taking his abilities from his private practice to Wall Street, Lindsay Rosenwald began using both finance specialization and his unique insights into the medical industry to work in an advisory capacity. This would become the foundation of the work for which he is best known.

After five years on Wall Street, Lindsay Rosenwald established the beginnings of the Paramount Group, including Paramount BioSciences and Paramount BioCapital, both founded in 1991 in order to provide a unique and effective structure to assist in locating and supporting new bioresearch and biotechnology companies that showed significant potential. The Paramount Group includes more than just these two major strands, however. It is a collection of major support pillars that help new groups gain a secure place in the market and overcome the challenges of starting out as a biorearch company. While Paramount BioSciences helps to locate the companies which show the most novel ideas and the most promising research, Paramount BioCapital helps gain the needed resources to fund them. Paramount BioCapital has raised just short of a billion dollars for its portfolio companies over the last two decades.

Paramount Corporate Development then helps these companies (once they have been located ans supported) by assisting them in making effective corporate plans, business strategies, and provide basic business and strategic support. These landmark companies have all been a significant part of Lindsay Rosenwald‘s contribution to the industry, and are behind his widely acknowledged reputation as one of the forerunners in the biomedical industry, both as a contributor, entrepreneur, and developer. Over the last two decades, repeated success has solidified this reputation. The companies that he has established, developed, or invested in, have had an immense impact on the industry as a whole. The contributions have not only been financially successfully, but revolutionary in the industry, making significant progress in treatment for prostate cancer, leukemia, dense tumors, and more. Lindsay Rosenwald and his contributions do not seem to be waning. Rather, over the last three years, we have seen a significant increase in the number of investments made. The innumerable accomplishments that Lindsay Rosenwald’s work has led to in the biotechnology and bioresearch fields include a few notable highlights. One of the portfolio companies of the Paramount group received the fastest approval time from the Food and Drug Administration that we have seen to date. From a financial perspective, we have seen major success, with notable examples like Sanctura – a company developed by the Paramount Group which sold for approximately $600 million. The impact on the medical field itself, with astonishing progress in areas like leukemia, tumor, and cancer treatment, are just a few of the more significant items of note. The acquisitions from outside companies may be one of the greatest signals of how successful Lindsay Rosenwald has been. Groups like Johnson & Johnson, Albany Molecular, and Myriad Pharmaceuticals, have acquired portfolio companies developed by the Paramount Group, and the total cost of acquisitions have exceed $1 billion. All of this success may root back to the double disciplines that Lindsay Rosenwald chose to pursue.

Having experience in both the financial sector and in medicine and biotechnology, Lindsay Rosenwald has been able to offer insights that are matched by few others in the history of modern healthcare. He is not only able to seek out those companies which show great potential, he is also able to accurately foresee the challenges they may face, and prepare them with resources and strategies to cope with those challenges successfully. In addition to real financial success for both himself, the Paramount Group, and his portfolio companies, Lindsay Rosenwald has selflessly established the Rosenwald foundation. This nonprofit organization has contributed millions of dollars to medical education institutions and other scientific communities, laying the groundwork for the revolutionary advances of the future. Lindsay Rosenwald has many accomplishments that he can successfully claim. He is the founder of the Paramount Group – a company which has led to some of the greatest pharmaceutical and biotechnology advancements over the last two decades. He is a successful entrepreneur and forerunner in the finance industry. His dual disciplines in finance and medicine have allowed him to have an impact that few others have had in the history of biomedicine, and in recent years, Lindsay Rosenwald is widely seen as the greatest contributor to the industry.

Lindsay Rosenwald – Paramount Group of Companies

2 comments

Posted on 5th April 2010 by admin in Home

, ,

Biotechnology has an increasingly significant impact on a number of life sectors and disciplines. Paramount Group of Companies founded by Lindsay Rosenwald has been working with biotechnology and life sciences for over 20 years. With a global impact on the biotechnology sector, Paramount developed, invested and supported more than 40 life sciences companies over the past 19 years, including 20 in the last 3 years. Current Portfolio Companies have over 40 product candidates that advance through clinical trials. Paramount has also a strong record on scientific, industrial, health and safety issues in biotechnology and pharmacy.

Paramount BioSciences, LLC, founded and managed by Dr. Lindsay A. Rosenwald, is focused on the in-licensing of novel therapeutic and other medical technologies and is involved in corporate companies incubation and governance as well as business development. It extensively supports infrastructure with the experience in licensing, corporate development, clinical operations, and navigation of regulatory pathways. Paramount BioCapital, Inc., a FINRA registered broker-dealer, is involved in raising capital for Paramount’s Portfolio Companies.

Paramount BioSciences Executive Leadership Team

Paramount BioSciences executive team has an extensive collective experience in biotechnology/pharmacy and financial operations.

Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, Founder of Paramount BioSciences. With over 20 years of experience in developing, financing, and investing in biotechnology and life science companies, Dr. Rosenwald has made a powerful contribution to the today’s biotechnology sector. He has also established a charitable foundation called The Rosenwald Foundation Inc., which deals with educational philanthropic research.

J. Jay Lobell, J.D., President and Chief Operating Officer, was a former partner at law firm Covington & Burling, where he provided business, litigation, and regulatory advice to financial institutions, corporations, and individuals.

Russell Ellison, M.D., Executive Vice President, has almost 30 years of senior management pharmaceutical experience in commercialization and drug development. His former positions as the Vice President of Clinical Development at Fibrogen, Inc. and the U.S. Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, USA prove his ability to successfully deal with complex financial and management operations.

Advantages of Paramount BioSciences Model

What makes Paramount BioScienses the preferred acquirer of drugs and development is their flexibility on structure of collaboration and licensing. They have all the assets and skills to rapidly execute, deal and begin development work and access to the capital necessary to develop new products. With a huge clinical and commercial experience and expertise, Paramount’s mission is to maximize value to in-licensed products. Portfolio Companies can be focused on the development of a few key products by providing committed resources (human and financial) as well as a top-tier management expertise, which is focused on a specific product or field.

The structure of Portfolio Company fosters the compound’s progression through to market, eliminating possibilities of the program being shelved.

Financing Models and Related Information

In the past, Paramount Portfolio Companies were publicly traded, via initial public offering, acquisition, reverse merger, or self-registration. The following models are now employed: partnership, merger and acquisition, as well as the Private Company model.

In addition to its own investment in Portfolio Companies, Paramount Group has also raised substantial capital from outside investors. Over the past 60 months more than $400 million was raised for Paramount companies. Such companies include Ziopharm Oncology ($37MM), Cougar Biosciences ($47MM; in conjunction with SG Cowen), and Chelsea Therapeutics ($22MM).

Dr. Lindsay Rosenwald has been able to attract experienced CEO and management staff from such companies and organizations as Serono, Pfizer, Genentech, Johnson & Johnson, Roche, Biogen Idec, Sanofi Aventis, Antigenics, and Celltech. This ensures that Paramount’s commercial and financial aspects always stay on top level.

Clinical Assets of Selected Public and Private Companies Funded by Paramount BioSciences

Keryx Biopharmaceuticals: Phase II Phosphate binder; Phase II drug (Perifosine) for oncology; Phase II drug for oncology (UCN-01)

Javelin Pharmaceuticals: Phase III drug Intranasal Morphine and Intranasal Ketamine for pain relief; Pre-MAA and Phase III Injectable Diclofenac

Cougar Biotechnology: Phase III drug (Abiraterone Acetate) for prostate cancer; Phase I/II drug (Noscapine) for NHL; Phase II drug (Seocalcitol) for prostate cancer

Ziopharm Oncology: Phase II/III drug for myeloma; Phase I/II drug for sarcoma; Phase II drug for breast cancer

Hana Biosciences: Phase II/III drug for hematological malignancies; Phase I drug for EGFR inhibitor rash; Phase II anti-folate for oncology; Phase I/II camptothecin for oncology

Manhattan Pharmaceuticals: Phase II/III drug for Atopic Dermatitis; Phase III sedative buccal spray; Phase III topical head lice preparation

Chelsea Therapeutics: Phase III drug for orthostatic hypotension; Phase II drug for rheumatoid arthritis; IND stage drug for inflammatory conditions

NovaDel Pharma: Buccal spray platform technology; buccal sprays for migraine, anxiety, sleep and multiple other indications under development

Vioquest Pharmaceuticals: Phase II AKT inhibitor for solid tumors and hematological malignancies; Pre-NDA compound for Leishmaniasis; Phase II PTP inhibitor for multiple tumor types; Phase II drug for chemo-induced Hand Foot Syndrome

Tracon Pharmaceuticals, Inc.: TRC-105: Anti-CD105 monoclonal antibody addressing major cancers (prostate, breast and renal cell); TRC-93: Humanized, affinity-matured IgG and retained specificity of murine parental IgM HUI77. This antibody is active in combination with chemotherapy. TRC-102: Small molecule inhibitor of base-excision repair, shown to reverse Temodar® resistance without added toxicity

Alacrity BioSciences, Inc.: ALTY-0501: 0.025% doxycycline inhibits MMP-9 breakdown of corneal barrier. This is a novel mechanism approach to the $500 MM+ dry eye market, which currently offers limited treatment options. ALTY-0601: Small peptide therapeutic with a unique mechanism of action to reduce intraocular pressure (IOP) in patients with ocular hypertension or primary open angle glaucoma

Cutanea Life Sciences, Inc.: CLS001: Omiganan pentahydrochloride is a patented, novel peptide used to treat rosacea that has demonstrated activity against a wide variety of microorganisms, including gram-positive and gram- negative bacteria and fungi. CLS002: Next generation injectible chitosan in soft tissue augmentation. CLS003: Ionic Contra Viral Therapy in development for the treatment of cutaneous warts.

Ventrus BioSciences, Inc.: VEN309: New chemical entity for the topical treatment of hemorrhoids; mechanism of action is to inhibit venous contraction and platelet aggregation, allowing normalization of blood flow. VEN307: Diltiazem cream for anal fissures. VEN308: Phenylephrine gel for fecal incontinence.

Mt Cook Pharma, Inc.: MCP101: TRPV1-agonist; an intravesical treatment for overactive bladder (OAB) and benign prostate hyperplasia (BPH) patients who fail oral medications. MCP202: Oral, first-line delta receptor agonist treatment for OAB and BPH. MCP201: Chemically novel, injectible, mixed opioid receptor agonist for serious pain

Indigo Pharmaceuticals, Inc.: INDI-702: Synthetically derived, oral small molecule for large, chronic, cardiovascular market. Possesses both phosphodiesterase (PDE) inhibitor activity and thromboxane A2 synthetase (TxA2) inhibitor activity and demonstrated increase in peak walking time (p=0.004) compared to placebo at 24 weeks.

Coronado BioSciences, Inc.: CNDO101 (5-imino-3-deoxydoxorubicin): Rationally designed anthracycline analogue with safety advantages – Structural elements responsible for cardio-toxicity has been eliminated. CNDO102 (NK cell activator): Immunotherapy targeting minimal residual disease. The compound has already shown positive efficacy in its ongoing Phase 1 Trial. CNDO103 (Bcl-2 family protein inhibitor platform): Rationally designed, pan-Bcl-2 inhibitor with multiple oncology applications.

Search engine optimization by SEO Design Solutions